697739-15-4

Basic information

• Product Name: Imidazo[1,5-a]pyridin-8-amine (9CI)
• Synonyms: Imidazo[1,5-a]pyridin-8-amine (9CI);Imidazo[1,5-a]pyridin-8-amine
• CAS NO: 697739-15-4
• Molecular Formula: C7H7N3
• Molecular Weight: 133.15058
• Product Categories: AMINETERTIARY
• Mol File: 697739-15-4.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Imidazo[1,5-a]pyridin-8-amine (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Imidazo[1,5-a]pyridin-8-amine (9CI)(697739-15-4)
• EPA Substance Registry System: Imidazo[1,5-a]pyridin-8-amine (9CI)(697739-15-4)

Safety Data

• Hazardous Substances Data: 697739-15-4(Hazardous Substances Data)

Usage

General Description

Imidazo[1,5-a]pyridin-8-amine (9CI) is a chemical compound with the molecular formula C9H8N4. It is a heterocyclic amine that contains both an imidazole and a pyridine ring in its structure. Imidazo[1,5-a]pyridin-8-amine (9CI) has potential applications in medicinal chemistry, particularly as a scaffold for designing new drugs. Imidazo[1,5-a]pyridin-8-amine (9CI) may also have biological activities, and it is being studied for its potential pharmacological properties. The compound's synthesis and characterization are also subjects of research interest in the field of organic chemistry.

Upstream product

• 697739-14-3 tert-butyl imidazo[1,5-a]pyridin-8-ylcarbamate 

Relevant articles and documents

AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN

the present invention provides a compound of formula (I): wherein V represents NR5, O, S, SO or S(O)2; W and X each independently represent CH or N; Y represents N, CH or C-Ar2, with the proviso that at least one, but no more than two, of W, X and Y are N; Z represents CH or C-Ar2, with the proviso that when Y is N or CH then Z is C-Ar2, and with the further proviso that when Y is C-Ar2 then Z is CH; Ar1 represents a fused 9 or 10 membered heterobicyclic ring system containing one, two, three or four heteroatoms selected from nitrogen, oxygen and sulfur, wherein at least one of the rings in said ring system is aromatic; Ar2 represents an aromatic ring selected from phenyl, pyridyl, pyrimidinyl and pyridazinyl which is optionally fused and substituted; R1 represents halogen, hydroxy, oxo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkoxy, C3-7cycloalkyl, C3-7cycloalkoxy, C3-5cycloalkylC1-4alkyl, cyano, nitro, SR6, SOR6, SO2R6, COR6, NR3COR6, CONR3R4, NR3SO2R6, SO2NR3R4, -(CH2)mcarboxy, esterified -(CH2)mcarboxy or -(CH2)mNR3R4; R2 represents hydrogen, halogen, hydroxy, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy, haloC1-6alkoxy, unsubstituted phenyl or phenyl substituted with one or two groups selected from halogen, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy or haloC1-6alkoxy; R3 and R4 are each independently hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl or fluoroC1-6alkyl; or R3 and R4 and the nitrogen atom to which they are attached together form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C1-4alkoxy, which ring may optionally contain as one of the said ring atoms an oxygen or a sulfur atom, S(O), S(O)2, or NR5; R5 represents hydrogen, C1-4alkyl, hydroxyC1-4alkyl or C1-4alkoxyC1-4alkyl; R6 represents hydrogen, C1-6alkyl, fluoroC1-6alkyl, C3-7cycloalkyl, unsubstituted phenyl, or phenyl substituted with one or two groups selected from halogen, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy or haloC1-6alkoxy; m is either zero or an integer from 1 to 4; n is either zero or an integer from 1 to 3; or a pharmaceutically acceptable salt, N-oxide or a prodrug thereof; a pharmaceutical composition comprising it; its use in methods of treatment; use of it for the manufacture of a medicament for treating VR-1 related conditions such as those in which pain and/or inflammation predominate; and methods of treatment using it.